Alnylam (ALNY) has 3 FDA products, PPS $125.80 with a high of $167, that's a smaller market-cap than BCRX once approved of Berotralstat. BCRX already has one revenue generating product,
ALNY has a larger number of outstanding shares, with revenues of $219 million. BCRX will have double the revenue of ALNY and less outstanding shares with BCRX 72% share structure being intuitional holdings, the squeeze of BCRX will be huge.
Numbers don't lie, BCRX is so undervalued that it's scary when Wall Street sees this quite monster's forecasted revenues and pipeline. I say a buyout is definitely in order.
Market Data 
Markets 
AI
